1. Scrip
  2. >>R&D

Kancera To Pursue Ex-AZ Asset Targeting Fractalkine Into Clinic

 
• By Sukaina Virji

Swedish drug developer Kancera has exercised an exclusive option to develop a former AstraZeneca drug candidate. The small molecule shares a mechanism of action with a clinical-stage therapeutic antibody from Eisai.

Homeless dog
Abandoned by AstraZeneca, fractalkine project gets new lease of life • Source: Shutterstock

Kancera will shortly start Phase I trials with a small molecule drug candidate that inhibits the Fractalkine receptor CX3CR1. Originally developed for multiple sclerosis, the project was abandoned by AstraZeneca PLC in 2013 when AstraZeneca sold its Södertälje facility in Sweden to Acturum.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.